£49m-turnover drug discovery firm makes key appointments
Manchester-based Concept Life Sciences, the integrated drug discovery, development and analytical services company, has celebrated ending its financial year with revenues of more than £49m with two key hires.
The company which employs more than 700 staff across 10 state-of the-art laboratories has announced the appointment of Dr Andrew Scott as head of bioassay development and screening and Magalie Ferbach as business development director for Southern and Central Europe.
Concept has strengthened its resources and increased capacity across all disciplines in 2017, and especially in translational biology services for small molecule programmes, with key appointments in scientific and business support services, the opening of 12,000sq ft of laboratory space at Alderley Park, Cheshire and the acquisition of Aquila Biomedical in Edinburgh.
The addition of Aquila opens up the large molecule arena to Concept, with specific therapeutic experience in immuno-oncology.
The expansion seen though 2017 will enable the company to increase its penetration in integrated discovery and development services and in complex analytical science across the agrochemical, environmental, and life sciences sectors.
Dr Andrew Scott has 20 years’ experience in senior scientific roles for pharmaceutical companies, biotechs and CROs, including Pfizer, AstraZeneca, Molplex and Sygnature Discovery.
Magalie Ferbach has 18 years’ experience in the agrochemicals business, most recently at Envigo where she was sales director for central Europe in crop protection and biocides.
Prior to Envigo she was at ANADIAG Laboratories/ANADIAG SAS where she held various roles including Business Development Manager, and Regulatory Expert. Magalie has a Bachelor’s degree and Diploma of Higher Education in Chemistry.
Concept executive chairman Michael Fort said:“2017 has been a pivotal year for Concept. We welcome Magalie and Andrew to the group at this exciting time in our development, and look forward to their contribution to our integrated discovery and development team.”
“Moving into 2018, we continue to search for complementary businesses in the UK and overseas that add to our current scientific offering, both in existing and in adjacent service lines.
“The business in on course for continued profitable growth of over 30% in 2018, as the Company expands and broadens its services offering, including increased reach in Europe and the United States.”
